*	O
*	O
*	O
most	O
patients	O
heal	O
within	O
4	O
weeks	O
;	O
some	O
patients	O
may	O
require	O
additional	O
therapy	O
to	O
achieve	O
healing	O
.	O

*	O
*	O
if	O
symptoms	O
do	O
not	O
resolve	O
completely	O
after	O
4	O
weeks	O
,	O
an	O
additional	O
course	O
of	O
treatment	O
may	O
be	O
considered	O
.	O

administration	O
instruction	O
s	O
swallow	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
whole	O
.	O

for	O
all	O
other	O
indications	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
can	O
be	O
taken	O
with	O
or	O
without	O
food	O
.	O

for	O
helicobacter	O
pylori	O
eradication	O
take	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
with	O
food	O
.	O

for	O
helicobacter	O
UNKNOWN_TOKEN	O
take	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
with	O
food	O
.	O

for	O
the	O
treatment	O
of	O
duodenal	O
ulcers	O
take	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
after	O
a	O
meal	O
.	O

if	O
it	O
is	O
almost	O
time	O
for	O
the	O
next	O
dose	O
,	O
skip	O
the	O
missed	O
dose	O
and	O
go	O
back	O
to	O
the	O
normal	O
schedule	O
.	O

indication	O
recommended	O
dosage	O
(	O
2	O
)	O
healing	O
of	O
erosive	O
or	O
ulcerative	O
gastroesophageal	O
reflux	O
disease	O
(	O
gerd	O
)	O
20	O
mg	O
once	O
daily	O
for	O
4	O
to	O
8	O
weeks	O
maintenance	O
of	O
healing	O
of	O
erosive	O
or	O
ulcerative	O
UNKNOWN_TOKEN	O
for	O
12	O
months	O
20	O
mg	O
once	O
daily	O
*	O
symptomatic	O
gerd	O
in	O
adults	O
20	O
mg	O
once	O
daily	O
for	O
4	O
weeks	O
healing	O
of	O
duodenal	O
ulcers	O
20	O
mg	O
once	O
daily	O
after	O
morning	O
meal	O
for	O
up	O
to	O
4	O
weeks	O
helicobacter	O
pylori	O
eradication	O
to	O
reduce	O
the	O
risk	O
of	O
duodenal	O
ulcer	O
recurrence	O
three	O
drug	O
regimen	O
:	O
UNKNOWN_TOKEN	O
UNKNOWN_TOKEN	O
1000	O
UNKNOWN_TOKEN	O
500	O
mg	O
all	O
three	O
medications	O
should	O
be	O
taken	O
twice	O
daily	O
with	O
morning	O
and	O
evening	O
meals	O
for	O
7	O
days	O
pathological	O
UNKNOWN_TOKEN	O
conditions	O
,	O
including	O
zollinger	O
-	O
ellison	O
syndrome	O
starting	O
dose	O
60	O
mg	O
once	O
daily	O
then	O
adjust	O
to	O
patient	O
needs	O
symptomatic	O
gerd	O
in	O
adolescents	O
12	O
years	O
of	O
age	O
and	O
older	O
20	O
mg	O
once	O
daily	O
for	O
up	O
to	O
8	O
weeks	O
administration	O
instructions	O
(	O
2	O
UNKNOWN_TOKEN	O
swallow	O
UNKNOWN_TOKEN	O
delayed	O
-	O
UNKNOWN_TOKEN	O
whole	O
.	O

the	O
use	O
of	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
is	O
not	O
recommended	O
for	O
use	O
in	O
pediatric	O
patients	O
1	O
year	O
to	O
less	O
than	O
12	O
years	O
of	O
age	O
because	O
the	O
lowest	O
available	O
tablet	O
strength	O
(	O
20	O
mg	O
)	O
exceeds	O
the	O
recommended	O
dose	O
for	O
these	O
patients	O
.	O

use	O
another	O
UNKNOWN_TOKEN	O
formulation	O
for	O
pediatric	O
patients	O
1	O
year	O
to	O
less	O
than	O
12	O
years	O
of	O
age	O
.	O

•	O
UNKNOWN_TOKEN	O
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
UNKNOWN_TOKEN	O
,	O
substituted	O
UNKNOWN_TOKEN	O
,	O
or	O
to	O
any	O
component	O
of	O
the	O
formulation	O
.	O

•	O
for	O
information	O
about	O
contraindications	O
of	O
antibacterial	O
agents	O
(	O
clarithromycin	O
and	O
amoxicillin	O
)	O
indicated	O
in	O
combination	O
with	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
,	O
refer	O
to	O
the	O
contraindications	O
section	O
of	O
their	O
package	O
inserts	O
.	O

hypersensitivity	O
reactions	O
may	O
include	O
anaphylaxis	O
,	O
anaphylactic	O
shock	O
,	O
angioedema	O
,	O
bronchospasm	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
urticaria	O
.	O

patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
to	O
UNKNOWN_TOKEN	O
)	O
.	O

ppis	O
,	O
including	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
,	O
are	O
contraindicated	O
in	O
patients	O
receiving	O
UNKNOWN_TOKEN	O
-	O
containing	O
products	O
(	O
UNKNOWN_TOKEN	O
)	O
.	O

UNKNOWN_TOKEN	O
,	O
including	O
UNKNOWN_TOKEN	O
,	O
are	O
contraindicated	S-Trigger
with	O
UNKNOWN_TOKEN	O
-	O
containing	O
products	O
.	O

refer	O
to	O
the	O
contraindications	O
section	O
of	O
the	O
prescribing	O
information	O
for	O
clarithromycin	S-Precipitant
and	O
amoxicillin	S-Precipitant
,	O
when	O
administered	O
in	O
combination	O
with	O
UNKNOWN_TOKEN	S-Precipitant
(	O
4	O
)	O
.	O

UNKNOWN_TOKEN	O
:	O
see	O
prescribing	O
information	O
for	O
UNKNOWN_TOKEN	S-Precipitant
for	O
dosing	O
information	O
.	O

combination	O
therapy	O
with	O
clarithromycin	O
and	O
amoxicillin	O
clinical	O
impact	O
:	O
concomitant	O
administration	O
of	O
clarithromycin	S-Precipitant
with	O
other	O
drugs	O
can	O
lead	O
to	O
serious	O
adverse	O
reactions	O
,	O
including	O
potentially	O
fatal	O
arrhythmias	O
,	O
and	O
UNKNOWN_TOKEN	O
.	O
amoxicillin	O
also	O
has	O
drug	O
interactions	O
.	O

consult	B-Trigger
the	I-Trigger
labeling	E-Trigger
of	O
concomitantly	O
used	O
drugs	B-Precipitant
to	I-Precipitant
obtain	I-Precipitant
further	I-Precipitant
information	I-Precipitant
about	O
interactions	O
with	O
ppis	O
.	O

decreased	B-Trigger
exposure	E-Trigger
of	O
some	O
antiretroviral	B-Precipitant
drugs	E-Precipitant
(	O
e.g.	O
,	O
UNKNOWN_TOKEN	S-Precipitant
,	O
UNKNOWN_TOKEN	S-Precipitant
,	O
and	O
UNKNOWN_TOKEN	S-Precipitant
)	O
when	O
used	O
concomitantly	O
with	O
UNKNOWN_TOKEN	S-Precipitant
may	O
reduce	B-Trigger
antiviral	O
effect	O
and	O
promote	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

digoxin	O
clinical	O
impact	O
:	O
potential	B-Trigger
for	I-Trigger
increased	B-Trigger
exposure	E-Trigger
of	O
digoxin	S-Precipitant
.	O

dose	B-Trigger
adjustment	E-Trigger
of	O
digoxin	S-Precipitant
may	O
be	O
needed	O
to	O
maintain	O
therapeutic	O
drug	O
concentrations	O
.	O

dose	B-Trigger
adjustment	E-Trigger
of	O
tacrolimus	S-Precipitant
may	O
be	O
needed	O
to	O
maintain	O
therapeutic	O
drug	O
concentrations	O
.	O

dose	B-Trigger
adjustment	E-Trigger
of	O
warfarin	S-Precipitant
may	O
be	O
needed	O
to	O
maintain	O
target	O
inr	O
range	O
.	O

drugs	O
dependent	O
on	O
gastric	O
ph	O
for	O
absorption	O
(	O
e.g.	O
,	O
ir	O
on	O
salts	S-Precipitant
,	O
UNKNOWN_TOKEN	S-Precipitant
,	O
UNKNOWN_TOKEN	S-Precipitant
,	O
UNKNOWN_TOKEN	S-Precipitant
,	O
UNKNOWN_TOKEN	S-Precipitant
ate	O
UNKNOWN_TOKEN	S-Precipitant
,	O
ketoconazole	S-Precipitant
,	O
itraconazole	S-Precipitant
)	O
clinical	O
impact	O
:	O
UNKNOWN_TOKEN	S-Precipitant
can	O
reduce	B-Trigger
the	I-Trigger
absorption	E-Trigger
of	O
other	O
drugs	O
due	O
to	O
its	O
effect	O
on	O
reducing	O
UNKNOWN_TOKEN	O
acidity	O
.	O

false	O
positive	O
urine	O
tests	O
for	O
thc	O
clinical	O
impact	O
:	O
there	O
have	O
been	O
reports	O
of	O
false	O
positive	O
urine	O
screening	O
tests	O
for	O
tetrahydrocannabinol	O
(	O
thc	O
)	O
in	O
patients	O
receiving	O
ppis	O
.	O

increased	B-Trigger
exposure	E-Trigger
of	O
other	O
antiretroviral	B-Precipitant
drugs	E-Precipitant
(	O
e.g.	O
,	O
UNKNOWN_TOKEN	S-Precipitant
)	O
when	O
used	O
concomitantly	O
with	O
UNKNOWN_TOKEN	S-Precipitant
may	O
increase	B-Trigger
toxicity	E-Trigger
.	O

interaction	O
with	O
secretin	O
stimulation	O
test	O
clinical	O
impact	O
:	O
hyper	O
-	O
response	O
in	O
gastrin	O
secretion	O
in	O
response	O
to	O
secretin	O
stimulation	O
test	O
,	O
falsely	O
suggesting	O
UNKNOWN_TOKEN	O
.	O

interactions	O
with	O
investigations	O
of	O
neuroendocrine	O
tumors	O
clinical	O
impact	O
:	O
serum	O
UNKNOWN_TOKEN	O
a	O
(	O
cga	O
)	O
levels	O
increase	O
secondary	O
to	O
ppi	O
-	O
induced	O
decreases	O
in	O
gastric	O
acidity	O
.	O

intervention	O
:	O
a	O
temporary	O
withdrawal	O
of	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
may	O
be	O
considered	O
in	O
some	O
patients	O
receiving	O
high	O
dose	O
methotrexate	O
administration	O
.	O

intervention	O
:	O
an	O
alternative	O
confirmatory	O
method	O
should	O
be	O
considered	O
to	O
verify	O
positive	O
results	O
.	O

intervention	O
:	O
monitor	S-Trigger
digoxin	S-Precipitant
concentrations	O
.	O

intervention	O
:	O
monitor	S-Trigger
inr	O
and	O
prothrombin	O
time	O
.	O

intervention	O
:	O
monitor	S-Trigger
tacrolimus	S-Precipitant
whole	O
blood	O
trough	O
concentrations	O
.	O

intervention	O
:	O
UNKNOWN_TOKEN	O
UNKNOWN_TOKEN	O
(	O
mmf	O
)	O
:	O
co	O
-	O
administration	O
of	O
ppis	O
in	O
healthy	O
subjects	O
and	O
in	O
transplant	O
patients	O
receiving	O
mmf	O
has	O
been	O
reported	O
to	O
reduce	B-Trigger
the	I-Trigger
exposure	E-Trigger
to	O
the	O
active	O
metabolite	O
,	O
UNKNOWN_TOKEN	B-Precipitant
acid	E-Precipitant
(	O
mpa	O
)	O
,	O
possibly	O
due	O
to	O
a	O
decrease	O
in	O
mmf	O
solubility	O
at	O
an	O
increased	O
gastric	O
ph.	O

intervention	O
:	O
UNKNOWN_TOKEN	O
UNKNOWN_TOKEN	O
products	O
:	O
concomitant	O
use	O
with	O
UNKNOWN_TOKEN	B-Precipitant
delayed	I-Precipitant
-	O
release	I-Precipitant
tablets	E-Precipitant
is	O
contraindicated	S-Trigger
.	O

intervention	O
:	O
see	O
contraindications	O
and	O
warnings	O
and	O
precautions	O
in	O
prescribing	O
information	O
for	O
clarithromycin	S-Precipitant
.	O
see	O
drug	O
interactions	O
in	O
prescribing	O
information	O
for	O
amoxicillin	S-Precipitant
.	O

intervention	O
:	O
temporarily	O
stop	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
treatment	O
at	O
least	O
14	O
days	O
before	O
assessing	O
cga	O
levels	O
and	O
consider	O
repeating	O
the	O
test	O
if	O
initial	O
cga	O
levels	O
are	O
high	O
.	O
for	O
monitoring	O
)	O
,	O
the	O
same	O
commercial	O
laboratory	O
should	O
be	O
used	O
for	O
testing	O
,	O
as	O
reference	O
ranges	O
between	O
tests	O
may	O
vary	O
.	O

intervention	O
:	O
temporarily	O
stop	O
treatment	O
with	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
at	O
least	O
14	O
days	O
before	O
assessing	O
to	O
allow	O
gastrin	O
levels	O
to	O
return	O
to	O
baseline	O
.	O

methotrexate	S-Precipitant
clinical	O
impact	O
:	O
concomitant	O
use	O
of	O
UNKNOWN_TOKEN	B-Precipitant
methotrexate	E-Precipitant
(	O
primarily	O
at	O
high	O
dose	O
)	O
may	O
elevate	O
and	O
prolong	B-Trigger
serum	I-Trigger
levels	E-Trigger
of	O
methotrexate	S-Precipitant
and/or	O
its	O
metabolite	B-Precipitant
UNKNOWN_TOKEN	E-Precipitant
,	O
possibly	O
leading	O
to	O
methotrexate	S-Precipitant
toxicities	S-Trigger
.	O

UNKNOWN_TOKEN	O
:	O
avoid	S-Trigger
concomitant	O
use	O
with	O
UNKNOWN_TOKEN	B-Precipitant
delayed	I-Precipitant
-	O
release	I-Precipitant
tablets	E-Precipitant
.	O

no	O
formal	O
drug	O
interaction	O
studies	O
of	O
methotrexate	O
with	O
ppis	O
have	O
been	O
conducted	O
.	O

other	O
UNKNOWN_TOKEN	O
:	O
see	O
prescribing	O
information	O
.	O

UNKNOWN_TOKEN	O
:	O
see	O
the	O
prescribing	O
information	O
for	O
UNKNOWN_TOKEN	S-Precipitant
and	O
monitor	S-Trigger
for	O
potential	O
UNKNOWN_TOKEN	O
toxicities	S-Trigger
.	O

see	O
full	O
prescribing	O
information	O
for	O
a	O
list	O
of	O
clinically	O
important	O
drug	O
interactions	O
(	O
7	O
)	O
.	O

see	B-Trigger
prescribing	I-Trigger
information	E-Trigger
for	O
UNKNOWN_TOKEN	S-Precipitant
.	O

see	B-Trigger
prescribing	I-Trigger
information	E-Trigger
for	O
tacrolimus	S-Precipitant
.	O

see	B-Trigger
prescribing	I-Trigger
information	E-Trigger
for	O
warfarin	S-Precipitant
.	O

tacrolimus	S-Precipitant
clinical	O
impact	O
:	O
potentially	O
increased	B-Trigger
exposure	E-Trigger
of	O
tacrolimus	S-Precipitant
,	O
especially	O
in	O
transplant	O
patients	O
who	O
are	O
intermediate	O
or	O
poor	B-Precipitant
UNKNOWN_TOKEN	I-Precipitant
of	I-Precipitant
cyp2c19	E-Precipitant
.	O

the	O
clinical	O
importance	O
and	O
the	O
mechanisms	O
behind	O
these	O
interactions	O
are	O
not	O
always	O
known	O
.	O

the	O
clinical	O
relevance	O
of	O
reduced	O
mpa	O
exposure	O
on	O
organ	O
rejection	O
has	O
not	O
been	O
established	O
in	O
transplant	O
patients	O
receiving	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
and	O
mmf	O
.	O

the	O
increased	O
cga	O
level	O
may	O
cause	O
false	O
positive	O
results	O
in	O
diagnostic	O
investigations	O
for	O
neuroendocrine	O
tumors	O
.	O

there	O
are	O
other	O
antiretroviral	O
drugs	O
which	O
do	O
not	O
result	O
in	O
clinically	O
relevant	O
interactions	O
UNKNOWN_TOKEN	O
.	O

use	O
UNKNOWN_TOKEN	O
delayed	O
-	O
release	O
tablets	O
with	O
caution	O
in	O
transplant	O
patients	O
receiving	O
UNKNOWN_TOKEN	O
the	O
prescribing	O
information	O
for	O
other	O
drugs	B-Precipitant
dependent	I-Precipitant
on	I-Precipitant
gastric	E-Precipitant
ph	O
for	O
absorption	O
.	O

warfarin	O
clinical	O
impact	O
:	O
increased	O
inr	O
and	O
prothrombin	O
time	O
in
